CytomX Therapeutics, Inc. — Form 8-K
Filed August 6, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 48/100
What the filing says
CytomX announced Q2 2026 results with $330.3M cash (excluding $37.0M Regeneron payment received in July 2026 for two additional bispecific targets). Varseta-M Phase 1 enrollment completed with 113 patients; registrational study planned for H1 2027. Regeneron collaboration expanded to cover up to 6 additional future targets with ~$4.0B total potential milestones. Board strengthened with oncology/regulatory hires. Q2 revenue declined to $1.4M from $18.7M YoY due to Bristol Myers Squibb collaboration completion; operating expenses increased $5.3M to $25.2M. Cash runway extended to at least H2 2028.
Why this rating
Pipeline expansion and $37M payment meaningful but clinical-stage; Regeneron deal valuable validation. Cash burn and revenue decline offset gains. Moderate near-term significance relative to $372M market cap.
See more from August 6, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.